{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:52:32Z","timestamp":1792601552893,"version":"4.5.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The rising global cancer burden underscores the urgent need for innovative and effective therapies. Molecular and cellular immunology advances have revolutionized cancer immunotherapy, transforming laboratory discoveries into clinical breakthroughs. The Second Bone Marrow Transplant and Cellular Therapy Congress, held in Abu Dhabi, United Arab Emirates (UAE), on October 26\n                    <jats:sup>th<\/jats:sup>\n                    - 27\n                    <jats:sup>th<\/jats:sup>\n                    , 2024, and sponsored by the Abu Dhabi Stem Cells Center (ADSCC), convened global experts to discuss cutting-edge developments in adoptive cell transfer (ACT); chimeric antigen receptor T-cell (CAR-T) therapy, tumor-infiltrating lymphocyte (TIL) engineering and T-cell receptor (TCR) innovations. Discussions covered key challenges such as tumor microenvironment (TME) resistance, antigen escape, manufacturing complexity, cost-effectiveness, and accessibility. Experts emphasized the crucial role of biomarker identification in optimizing patient selection and improving treatment efficacy. Additionally, emerging strategies were highlighted to enhance the durability and specificity of cellular therapies, including next-generation CAR-T designs, combination approaches, and novel gene-editing technologies. With over 2,300 participants from academia, research, and healthcare, the event fostered international collaborations and knowledge exchange. The ADSCC continues to play a pivotal role in integrating advanced cellular therapies into healthcare systems, contributing to the expansion of precision oncology in the UAE and beyond. This review analyzes the latest advances in immunotherapy, highlighting their clinical impact, challenges, and future directions in the evolving landscape of cancer treatment, as debated during the congress.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1650023","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:38:05Z","timestamp":1768891085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024"],"prefix":"10.3389","volume":"16","author":[{"given":"Gisela Maria","family":"Su\u00e1rez Formigo","sequence":"first","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]},{"name":"College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaima","family":"Mazorra","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthia","family":"Olexen","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Abdel Hadi","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]},{"name":"Oncology\/Oncology, Children\u2019s University Hospital","place":["T\u00fcbingen, Germany"]},{"name":"St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Alfonso","family":"Bencomo Hernandez","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inas","family":"El Najjar","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]},{"name":"College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Coukos","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Lausanne University Hospital","place":["Lausanne, Switzerland"]},{"name":"Department of Oncology, Lausanne University Hospital","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Sabzevari","sequence":"additional","affiliation":[{"name":"Precigen, Inc.","place":["Germantown, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bollard","sequence":"additional","affiliation":[{"name":"Children\u2019s National Hospital","place":["Washington, DC, United States"]},{"name":"George Washington University","place":["Washington, DC, United States"]},{"name":"Translational Research and Innovation, GW Cancer Center","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Couriel","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah","place":["Salt Lake, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wald","sequence":"additional","affiliation":[{"name":"Kure.ai","place":["Cleveland, OH, United States"]},{"name":"Immune Oncology Program, Case Comprehensive Cancer Center","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hamieh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Meyer Cancer Center, Weill Cornell Medicine","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Josep Carreras Leukemia Research Institute","place":["Barcelona, Spain"]},{"name":"Hematology Service, Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Al Kaabi","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yendry","family":"Ventura-Carmenate","sequence":"additional","affiliation":[{"name":"Abu Dhabi Stem Cells Center","place":["Abu Dhabi, United Arab Emirates"]},{"name":"College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"B1","unstructured":"World health statistics\n          \n          \n          \n          2022"},{"key":"B2","unstructured":"Global cancer observatory\n          \n          \n          2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract12060101","article-title":"The state of cancer care in the United Arab Emirates in 2022","volume":"12","author":"Al-Shamsi","year":"2022","journal-title":"Clinics practice"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00247","article-title":"Breast cancer in the United Arab Emirates","volume":"9","author":"Al-Shamsi","year":"2023","journal-title":"JCO Global Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.31080\/ASCB.2020.04.0267","article-title":"Early Onset Colorectal Cancer in the United Arab Emirates, Where do we Stand","volume":"4","author":"Humaid OA-S","year":"2020","journal-title":"Acta Sci Med Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Trans Oncol"},{"key":"B7","unstructured":"Cancer incidence in United Arab Emirates. Anual Report of the UAE-National Cancer Registry 2021"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040835","article-title":"T cell based immunotherapy for cancer: approaches and strategies","volume":"11","author":"Want","year":"2023","journal-title":"Vaccines"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarran","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood marrow transplantation: J Am Soc Blood Marrow Transplantation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"New Engl J Med"},{"key":"B22","unstructured":"FDA approves first cellular therapy to treat patients with unresectable or metastatic melanoma\n          \n          \n          \n          2024"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144\u201301 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","volume":"35","author":"Martin-Lluesma","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B25","unstructured":"Multicenter phase II trial of LN-145 tumor-infiltrating lymphocyte therapy plus pembrolizumab in patients with immune checkpoint inhibitor\u2013na\u00efve metastatic non\u2013small cell lung cancer\n          \n          \n            \n              Schoenfeld\n              A\n            \n            \n              He\n              K\n            \n            \n              Chesney\n              J\n            \n            \n              Garon\n              E\n            \n            \n              Nieva\n              J\n            \n            \n              Sacher\n              A"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","article-title":"Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma","volume":"57","author":"Chiffelle","year":"2024","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7995","article-title":"Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma","volume":"9","author":"Barras","year":"2024","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001.30:10.1126\/science.aaa4971","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01072-6","article-title":"Sensitive identification of neoantigens and cognate TCRs in human solid tumors","volume":"40","author":"Arnaud","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1174","article-title":"Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells","volume":"13","author":"Arnaud","year":"2023","journal-title":"Clin Trans Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MOP.0000000000000445","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"29","author":"Llaurador","year":"2017","journal-title":"Curr Opin pediatrics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010832","article-title":"Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children\u2019s Oncology Group study","volume":"8","author":"Wistinghausen","year":"2024","journal-title":"Blood advances"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.04.009","article-title":"HIV-specific T cells generated from naive T cells suppress HIV in vitro and recognize wide epitope breadths","volume":"26","author":"Patel","year":"2018","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood advances"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00177","article-title":"Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: A phase I study","volume":"37","author":"Hont","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s10238-025-01769-x","article-title":"WT1 gene: a potential therapeutic target for multiple cancer treatment strategies","volume":"25","author":"Hirahata","year":"2025","journal-title":"Clin Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.10.010","article-title":"Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-beta","volume":"27","author":"Chaudhry","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12967-019-2055-4","article-title":"Medulloblastoma rendered susceptible to NK-cell attack by TGFbeta neutralization","volume":"17","author":"Powell","year":"2019","journal-title":"J Trans Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"New Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with relapsed\/refractory large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012240","article-title":"Don\u2019t keep me waiting\u201d: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes","volume":"8","author":"Vadgama","year":"2024","journal-title":"Blood advances"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2024-206596","article-title":"Phase I study results of UF-Kure19, a CAR-T product manufactured in less than 1 day, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma","volume":"144","author":"Deng","year":"2024","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Trans Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal transduction targeted Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary Malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"New Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413685","article-title":"Current non-viral-based strategies to manufacture CAR-T cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3791\/50070","article-title":"Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood","volume":"72","author":"Huls","year":"2013","journal-title":"J visualized experiments: JoVE"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0291-z","article-title":"A highly soluble Sleeping Beauty transposase improves control of gene insertion","volume":"37","author":"Querques","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415328","article-title":"Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia","volume":"15","author":"Mucha","year":"2024","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.12.020","article-title":"CAR T cell generation by piggyBac transposition from linear doggybone DNA vectors requires transposon DNA-flanking regions","volume":"17","author":"Bishop","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.iotech.2023.100375","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immuno-oncology technology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1332","article-title":"Transposon-mediated genome manipulation in vertebrates","volume":"6","author":"Ivics","year":"2009","journal-title":"Nat Methods"},{"key":"B72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: A key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth factor Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1182\/blood-2024-207448","article-title":"Establishment of CD19-CAR-T cell production and treatment of non-Hodgkin lymphoma in the United Arab Emirates","volume":"144","author":"Abu Haleeqa","year":"2024","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169142","article-title":"Phase 1\/1b safety study of PRGN-3006 ultraCAR-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther oncolytics"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"key":"B78","unstructured":"Modified immune cells (Autologous CAR T cells) in treating patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer. Identifier: NCT03907527\n          \n          \n          Sponsor: Precigen, Inc"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468660","article-title":"Moving T memory stem cells to the clinic","volume":"121","author":"Gattinoni","year":"2013","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904497","article-title":"CAR T-cell therapy predictive response markers in diffuse large B-cell lymphoma and therapeutic options after CART19 failure","volume":"13","author":"Caballero","year":"2022","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41417-022-00518-6","article-title":"High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion","volume":"30","author":"Caballero","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e1268","DOI":"10.1002\/cti2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Alvarez-Fernandez","year":"2021","journal-title":"Clin Trans Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026758","article-title":"Hsp-car30 with a high proportion of less-differentiated T cells promotes durable responses in refractory cd30+ Lymphoma","volume":"145","author":"Caballero Gonzalez","year":"2025","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer discovery"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00744-x","article-title":"Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies","volume":"5","author":"Dobrin","year":"2024","journal-title":"Nat cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological Malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041003","article-title":"Systematic review on CAR-T cell clinical trials up to 2022: academic center input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"B92","unstructured":"CAR-T cell therapy market \u2013 global industry analysis and forecast, 2024-2030\n          \n          \n          \n          2024"},{"key":"B93","unstructured":"Gene, cell, + RNA therapy landscape report, Q3 quarterly data report 2024\n          \n          \n          \n          2024"},{"key":"B94","doi-asserted-by":"publisher","first-page":"101136","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: Focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B96","doi-asserted-by":"publisher","first-page":"105041","DOI":"10.1016\/j.critrevonc.2025.105041","article-title":"Advancing CAR-T cell manufacturing in Latin America: Current landscape, future directions, and challenges","volume":"217","author":"Toro-Pedroza","year":"2025","journal-title":"Crit Rev oncology\/hematology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s12672-025-03282-9","article-title":"CAR-T cell therapy in China: innovations, challenges, and strategic pathways","volume":"16","author":"Yan","year":"2025","journal-title":"Discover Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"B99","unstructured":"Weighing the cost and value of CAR T-cell therapy: A roundtable discussion with Carl H. June, Sagar Lonial, David G. Maloney and Pascal Touchon\n          \n          \n            \n              Cavallo\n              J\n            \n          \n          \n          2018"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone marrow transplantation"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05131-7","article-title":"Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature","volume":"102","author":"Mercadal","year":"2023","journal-title":"Ann hematology"},{"key":"B102","volume-title":"Risk evaluation and mitigation strategies (REMS)","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1650023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:38:22Z","timestamp":1771918702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1650023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":102,"alternative-id":["10.3389\/fimmu.2025.1650023"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1650023","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1650023"}}